The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 05, 2026

Filed:

Nov. 19, 2021
Applicant:

Tempus Ai, Inc., Chicago, IL (US);

Inventors:

Denise Lau, Chicago, IL (US);

Aly A. Khan, Chicago, IL (US);

Yinjie Gao, Los Angeles, CA (US);

Michelle Marie Stein, Chicago, IL (US);

Ameen Salahudeen, Oak Park, IL (US);

Timothy Rand, Chicago, IL (US);

Sonal Khare, Chicago, IL (US);

Assignee:

Tempus AI, Inc., Chicago, IL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); C12Q 1/6869 (2018.01); G16B 25/10 (2019.01); G16B 30/00 (2019.01); G16H 50/20 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12Q 1/6869 (2013.01); G16B 25/10 (2019.02); G16H 50/20 (2018.01); C12Q 2600/112 (2013.01); G16B 30/00 (2019.02);
Abstract

Disclosed herein are systems, methods, and compositions for treating a subject diagnosed with, or suffering from cancer. In some embodiments, the method comprises determining whether a tumor sample from the subject includes a cytotoxic gene signature, and treating the subject based on the determination. In some embodiments, the subject has or is suspected of having a loss of heterozygosity in human leukocyte antigen (HLA) class I genes. In some embodiments, the therapy comprises one or more checkpoint inhibitors. In some embodiments, the cancer is colorectal, uterine, stomach, lung, skin, head or neck, or non-small cell lung carcinoma.


Find Patent Forward Citations

Loading…